NCT02160366|Unknown
Loading search results
Sponsor study identifier
Secondary identifiers
observational
2,000
1 country
1
Study Start
September 27, 2010
Actual (reported)Primary Completion
September 27, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 27, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The goal of this laboratory research study is to collect and analyze treatment, molecular profiling and biomarker data. The results of the data analysis will be used to better understand how to characterize tumors and identify therapies that may be tailored to individual patients and to identify and/or predict side effects that may occur and/or predict which therapies may be best for participants. Research may also be done on your existing tissue to identify new biomarkers.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 27, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 27, 2010
Actual (reported)June 4, 2014
Actual (reported)June 10, 2014
Actual (reported)September 27, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 27, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Comparison of Biomarker Profiling to Treatment Outcome
For correlating marker profiles with response to treatment, univariate and multivariate (multiple covariates) logistic regression used, with response status taken as outcome variable. Distributions of time-to-event outcomes estimated using Kaplan-Meier curves, and these distributions compared among groups using log rank test.
2 months
Advanced cancer participants
Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients referred to the Clinical Center for Targeted Therapy at UT MD Anderson Cancer Center in Houston, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Weitz J, Nishizaki D, Liau J, Patel J, Ng I, Sun S, Ramms D, Zou J, Wishart B, Rull J, Baumgartner J, Kelly K, White R, Veerapong J, Hosseini M, Patel H, Botta G, Gutkind JS, Tiriac H, Kato S, Lowy AM. Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations. J Clin Oncol. 2025 Feb 20;43(6):705-715. doi: 10.1200/JCO.24.00511. Epub 2024 Oct 16.
Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
Filip Janku, MD, PHD
M.D. Anderson Cancer Center
First Submitted
June 4, 2014
First Posted
June 10, 2014
Study Start
September 27, 2010
Actual (reported)Primary Completion
September 27, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Genomic Profiling Assay in Phase I
Contact the study team to confirm eligibility.
Study Completion
September 27, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 10, 2020
Record last verified: 2020-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: